Slide 1: Xcelerate, Inc. - One Step Ahead
(75<V) XCELERATE, INC. S2ast OTC: XCRT One Step Ahead
Slide 2: The Healthcare Challenge
The Healthcare Challenge. Healthcare is not failing due to lack of innovation-it is failing to translate existing innovation from engineering into clinical care. Healthcare innovation is constrained not by lack of technology, but by a structural disconnect between advanced non-medical engineering an
Slide 3: Our Smart Solution
Our Smart Solution Translational Intelligence Platform Builds an internationally recognized network of clinicians and engineers to identify underutilized engineering breakthroughs and intellectual property with latent medical applications. Acquisition-Led Innovation Strategy Sources and acquires tec
Slide 4: Our Smart Solution
Our Smart Solution Clinical Development Ecosystem Combines engineering, clinical care, and business operations within a single controlled environment, enabling real-world testing, iteration, and validation. Low Cost Commercialization Model Sources and acquires technology at the engineering and paten
Slide 5: About Xcelerate Inc.
About Xcelerate seeks to acquire rather Xcelerate Inc. than develop its technology / healthcare delivery. We understand that engineering advancements in non-medical fields often have unrealized applications in medical technology & clinical care and the silos existing between advanced engineering One
Slide 6: Our Vision & Mission
Our Vision Our Vision & Mission A world where breakthrough medical innovations reach every patient quickly, affordably, and equitably. One Step Ahead Our Mission To bridge engineering and clinical care by accelerating medtech innovation from concept to real-world use, reducing development barriers,
Slide 7: Market Opportunity
Market Opportunity 01 02 03 $600B+ Global $2T+ Global $30B–$70B Annual Xcelerate targets the MedTech Market Healthcare Spending MedTech M&A inefficiency gap within a Efficiency Gap Activity $600B+ medtech The global medical Global healthcare The medtech sector market embedded in a technology market
Slide 8: Target Audience
Target Audience Engineering & IP Owners Healthcare & Non-medical engineering firms, Commercialization Partners research institutions, universities, and Clinical care facilities, healthcare patent holders with technologies that operators, strategic acquirers, and Early-Stage MedTech investors support
Slide 9: Our Growth Journey
Our Growth Journey 01 2020-2021 02 2022-2023 03 2024-2025 04 2026+ Vision, Foundation & IP Dual-Revenue Scaling Strategic Divestment & AI Medtech Scale & Acquisition Pivot Deployment New business plan launched Expanded into Conducted Transitioned the (May 2020). consumer healthcare comprehensive cap
Slide 10: WHY Xcelerate Acquired Afya SASA
WHY Xcelerate Acquired Afya SASA Expanding Xcelerate Beyond MedTech IP Into Scalable AI Healthcare Delivery The Challenge Why AFYA SASA Matters How This Benefits Xcelerate Traditional MedTech Afya Sasa creates a healthcare commercialization can face: delivery platform Diversifies Revenue Potential M
Slide 11: Strategic Synergies & Long Term Value Creation
Strategic Synergies & Long Term Value Creation How Afya Sasa enhances the Xcelerate ecosystem AI & Digital Health Platform AI triage, virtual care and digital Healthcare Network Access healthcare workflow to deliver Clinics accesible, affordable care at scale. Hospitals Pharmacies Physicians Emergin
Slide 12: Meet The CEO
Meet The CEO Michael O'Shea Chief Executive Officer Mike O'Shea is a forensic accountant and licensed financial investigator. He has worked closely with such agencies as the Federal Deposit Insurance Corporation, Resolution Trust Corporation, FBI, Office of the Controller of the Currency, US Secret
Slide 13: Meet The Directors
Meet The Directors Jason Householder Jon Wilken Director Director Jason Householder, Co-Founder and CEO of Charlotte based Jon Wilken , President and CEO of HS Pharmaceuticals, is a 30- LenDRgroup Consulting, has more than a decade of year veteran of the retail food industry. He is the former experi
Slide 14: Meet The Research Team
Meet The Research Team Dr. Ania Glisovic Chief Science Officer Dr. Glisovic received her PhD in X-Ray and Material Physics from Germany’s Georg-August Universitat in 2007. She went on to become the head of the R&D Laboratory, Chief Science Officer, and R&D Project Leader for the Fraunhoffer Institut
Slide 15: Meet The Advisory Board
Meet The Advisory Board Dr. Barry Marshall Dr. Dilan B. Ellegala AC. FRACP, FAA, FRS, MBBS-UWA MD, FAANS Professor Barry Morshall is a Nobel Prize Laureate, Professor of Clinical Dr. Ellegolo hos been ot the forefront of clinicol core ond medicol Microbiology at The University of Western Australia.
Slide 16: Corporate Information
Corporate Information Corporate Structure Symbol: XCRT Cusip: 98401T105 U.S. Reporting: SEC Reporting - Reg A Shell: No Shares Authorized: 1,000,000,000 Shares outstanding: 434,446,072 Restricted: 287,319,635 Unrestricted: 147,126,437 Public Float: 113,254,438 Information as of 6/30/2026
Slide 17: Come Join Us!
Come Join Us! 854-900-2020 info@xcelerate.global www.Xcelerate.global